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ABSTRACT 
Cone beam computed tomography (CBCT) is an x-ray modality providing three-dimensional 
x-ray images. CBCT devices have high resolution compared to traditional medical CT, 
making them suitable for examination of fine details. However, CBCT devices are worse at 
showing contrast differences, making them less suitable for examinations of soft tissue such 
as the brain and many other internal organs. An x-ray modality suitable for imaging of small 
details and hard tissue fits dental and maxillofacial radiology well. After the introduction of 
dentomaxillofacial CBCT in 1998, CBCT examinations have spread to become a common 
and important diagnostic tool in odontology. Today, CBCT examinations complement or 
replace examinations previously performed by other methods. 
When choosing an x-ray imaging modality and examination parameters, concern must be 
taken for the diagnostic value and the radiation dose. The examination should be chosen to 
provide as low radiation dose as possible while not sacrificing the diagnostic value. In order 
to provide guidelines on the use of CBCT, scientific knowledge on CBCT and alternative 
examinations are needed. What is the radiation dose for different examinations and how does 
the examination affect diagnosis and treatment? This thesis aims to provide additional 
information in this field, to provide reference data when considering the choice of 
examination and the establishment of guidelines. 
In the first paper, examinations of the temporomandibular joint, using CBCT and traditional 
medical multi-detector CT (MDCT), were compared to determine if CBCT examinations 
would result in lower radiation dose. The examinations were optimized to find the lowest 
suitable dose levels, and at these optimized dose levels no significant difference was found 
between CBCT and MDCT. 
The second paper investigated the radiation dose from multiple different x-ray examinations 
of possible resorption impacted maxillary canines in children. CBCT examinations were 
compared to two-dimensional examinations using intraoral radiographs, and in some cases 
panoramic radiographs. CBCT examinations ranged from 15 to 140 times higher radiation 
dose, depending on x-ray device. 
The third paper investigated the possibility of reducing the image size, and therefore the x-ray 
dose, in panoramic radiographs. A full-size panoramic radiograph was required in 20% of 
adult patient cases. The introduction of two different image sizes for adult patients would 
reduce the collective radiation dose from panoramic examinations by about 40% in our 
university clinic. 
The fourth paper investigated radiation doses from different examinations and settings using 
the Newtom 5G CBCT device. This CBCT model use automatic exposure control and does 
not allow manual adjustment of exposure parameters. The resulting effective doses should be 
applicable to examinations of adult patients using this CBCT model.  
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ABBREVIATIONS AND GLOSSARY 
CBCT Cone-beam computed tomography 
CNR Contrast-to-noise ratio 
CT Computed tomography 
CTDI Computed tomography dose index 
CsI Cesium iodine 
D Absorbed dose, unit Gy. 
DAP Dose-area product 
DLP Dose-length product 
DVT Digital volumetric tomography. A synonym for 
dentomaxillofacial CBCT. 
E Effective dose 
FOV Field of view. Defined as diameter × height for CBCT. 
Gy Gray. 𝐽 𝑘𝑔⁄  Unit for kerma and for absorbed dose. 
𝐻𝑡 Mean organ dose for tissue t 
HVL Half-value layer, a measure of energy in an x-ray spectrum. 
ICRP International commission on radiological protection 
ICRU International commission on radiation units and 
measurements 
K Kerma (Kinetic energy released in mater), unit Gy 
mA Milliampere, tube current  
mAs Milliampere-seconds, tube current-exposure time product 
MDCT Multi-detector computed tomography. Often used as a 
synonym for conventional medical CT in the literature, in 
contrast to CBCT. 
MOSFET Metal oxide semiconductor field effect transistor 
MSCT Multi-slice computed tomography. A synonym for MDCT. 
Often used as a synonym for conventional medical CT in the 
literature, in contrast to CBCT. 
s Experimentally determined standard deviation. 
Sv Sievert. Unit for effective dos and for equivalent dose. 
TLD Thermoluminescent dosimeter 
TM50 Endosteum. Not the actual endosteum, but the radiological 
surrogate tissue representing the osteoprogenitor cells. 
Defined as a 50 µm layer inside the trabecular cavities and 
lining the medullary cavity.   
TMJ Temporomandibular joint 
Type A uncertainty Uncertainty determined statistically through repeated 
measurements. 
Type B uncertainty Uncertainty determined through different methods from type 
A.  
wt Effective dose tissue weighting factor for tissue t 
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1 INTRODUCTION 
1.1 PURPOSE 
Dentomaxillofacial cone-beam computed tomography (CBCT), also called digital volumetric 
tomography (DVT), flat-detector CT or flat-panel CT, is a relatively new radiological 
modality. It was introduced in 1998 and has quickly grown to become common throughout 
dento-maxillofacial radiology, complementing or replacing other imaging modalities. With 
the introduction of a new x-ray modality the two basic principles of radiation protection must 
be considered: justification and optimization. In terms of radiology these concepts can be 
summarized as: “When should we use CBCT?” and “How should we use CBCT?”  
In order to establish guidelines addressing these two basic questions, several aspects must be 
considered. In the case of when, the principal aspect is the diagnostic efficiency. How 
accurate is CBCT compare to other modalities on a given diagnostic task? And ultimately, 
how does this diagnostic information affect the choice of treatment? Other important 
considerations are radiation dose and economic cost; if several modalities provide sufficient 
diagnostic properties for the tasks at hand, the one providing the lowest radiation dose should 
be used. Additionally, within each radiological modality, there are aspects affecting the image 
quality/general diagnostic value and radiation dose. Therefore, in order to optimize the 
radiation dose, examination protocols should take the diagnostic need for the specific task 
and the specific patient into account. In addition, due to limited resources, the economic cost 
of an imaging modality must be considered. 
To establish such evidence-based guidelines there is a need for a scientific knowledge base 
regarding the aspects mentioned above. What are the diagnostic, radiation dose and economic 
properties of CBCT and the alternative modalities for different examinations? It is in this 
field the current thesis acts, providing reference information where prior knowledge is 
lacking, with an emphasis on dosimetry. 
When planning the work covered in this thesis, we have primarily looked at Cone Beam CT 
for Dental and Maxillofacial Radiology: Evidence-based Guidelines produced by the 
SEDENTEXCT project and published by the European Commission in 2012.1 
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1.2 WHAT IS CBCT? 
CBCT is at its core a type of computed tomography, i.e., an x-ray imaging modality where 
several x-ray images are acquired from many angles around an object of interest, and from 
these 2D-projection images cross-sectional images are computed. Within medicine and 
odontology, this allows us to get a complete, non-overlapping, view into the patient without 
resorting to the scalpel. In contrast, conventional x-ray images are summation images, where 
all structures along the x-ray beam are shown overlapping, sometimes hiding abnormalities 
behind more distinct normal structures. 
CBCT was first introduced in odontology by Mozzo et al. in 1998.2 Since then, CBCT has 
quickly reached wide acceptance and adoption within dento-maxillofacial radiology. The 
adoption of CBCT has been slower within medical diagnostic radiology, but CBCT can today 
be found within interventional radiology, surgery, mammography and skeletal radiology as 
well as within radiotherapy. However, the x-ray imaging modality CBCT is, surprisingly, not 
obvious to define.  
 
1.2.1 What is the difference between CBCT and “regular” CT? 
To describe the difference between cone-beam CT and multi detector CT we must first define 
a number of technical terms. The size of the x-ray field in CT can be defined by the fan angle, 
in the plane of rotation, and the cone angle, perpendicular to the plane of rotation (Figure 1). 
Conventional medical CT (MDCT and earlier single detector row CT) use a small cone angle 
and larger fan angle, giving the x-ray field a “fan-like” shape. As compared to MDCT, CBCT 
generally uses a larger cone angle and smaller fan angle, giving the x-ray field a rectangular 
cone shape. 
 
Figure 1 Fan angle and cone angle of a CT x-ray field. 
Early CT reconstruction assumed parallel rays, which require low cone angles. With the 
introduction of MDCT with an increasing number of detector rows, the cone angles also 
increased. With increasing cone angles the assumption of parallel rays breaks down, requiring 
corrections such as the Feldkamp cone-beam algorithm.3 Up to about four-detector-row 
MDCT images could be reconstructed without cone-beam correction, but all modern MDCT 
use cone-beam algorithms.4 
X-ray field 
X-ray source 
Cone angle 
Fan angle 
Axis of rotation 
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Thus, it is not the cone angle that defines what is and is not called a CBCT device. The ICRP 
report on radiation protection in CBCT (ICRP 129) defines it as a CT with an area detector, 
acquiring a 3D volumetric image in one rotation.5 In practice, this means that apart from a 
large cone angle and large z-coverage, we need a detector with a very small pixel pitch to 
provide sufficient z-resolution. In all modern CBCT this takes the shape of a flat-panel 
detector with a CsI scintillator, and it is this detector that gives CBCT most of its 
characteristics. 
A flat-panel CsI detector allows for thick scintillation layers with minor reduction in 
resolution, thus maintaining relatively high sensitivity in high-resolution imaging. Compared 
to a MDCT detector array, a CBCT detector will allow higher spatial resolution. However, 
this comes at the price of image contrast. The CBCT detectors are not as sensitive as MDCT 
detectors and in addition, the smaller voxel sizes used in CBCT results in noisier images 
unless the radiation dose is increased to compensate. Another drawback with flat-panel 
detectors is that CsI is a relatively slow scintillator, requiring slower rotation times to avoid 
problems with detector afterglow. This, in turn, makes CBCT more prone to motion artifacts 
compared to MDCT. 
In effect, we have in CBCT a CT modality suitable for imaging of small details and high-
contrast objects such as bone or iodine contrast medium but unsuitable for low-contrast 
objects such as soft tissue. This makes CBCT excellent in dentistry with its high-contrast 
teeth and bone, and requirement to detect tiny lesions. Dental CBCT, in addition, often make 
use of volume-of-interest imaging, CT images with small radius limited to the object of 
interest, to reduce the x-ray field and thereby the radiation dose compared to MDCT. 
1.2.2 The effect of different examination parameters 
1.2.2.1 What do we want to see? 
Two aspects affecting diagnostic image quality are spatial resolution, how small objects can 
we see, and contrast resolution, how small contrast can we see. The contrast resolution 
depends on the noise inside the x-ray image; if an object’s contrast is small compared to the 
noise it will be hard or impossible to distinguish the object (Figure 2). The noise in an x-ray 
image will increase at a lower radiation dose. Thus, the radiation dose and image quality are 
intimately connected. Our diagnostic requirements will determine the dose level needed for 
the image. 
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Figure 2 Three images with the same contrast but increasing levels of noise. 
Image from: Diagnostic Radiology Physics: A Handbook for Teachers and Students. International atomic energy 
agency, 2014. © IAEA 
1.2.2.2 X-ray tube parameters 
The x-ray beam quality and radiation output are mostly determined by the following x-ray 
tube parameters: tube current-exposure time product (mAs), tube voltage (kV) and tube 
filtration. 
Both tube current and exposure time are directly proportional to the radiation dose and are 
therefore commonly combined into mAs when described and in exposure settings. Depending 
on the x-ray modality one or both of these parameters can be adjusted, but the results in terms 
of dose are the same.  
Tube voltage is the voltage between the cathode and anode inside the x-ray tube. This 
determines the maximum x-ray energy and affects the x-ray spectrum. The effect of tube 
voltage on radiation dose is more complex, but, all other parameters being equal, a higher 
tube voltage will result in a higher dose.  
The tube filtration affects the shape of the x-ray spectrum. Additional filtration is added to 
reduce the low energy parts of the spectrum; higher filtration will generally reduce the dose 
but will disproportionally affect the lower energies, thus raising the mean energy of the 
spectrum (Figure 3).  
  5 
  
Figure 3 Simulated x-ray spectrum from an early version of the Promax3D CBCT without copper filtration 
compared to later spectra with copper filtration. 
There are complex reasons for wanting a certain x-ray energy. At lower x-ray energy the 
contrast between different materials increases. Thus, it becomes easier to distinguish low-
contrast variations in tissue, especially subtler differences as in soft tissues. However, low 
energies are also more likely to interact with matter and at too low energy almost all rays will 
be absorbed inside the patient, resulting in radiation dose with little portion contributing to 
the image. The optimal energy (in terms of image quality per patient dose) will vary due to 
the material and thickness of the examined objects/tissues, as well as the effectiveness of the 
image detector at different energies. 
1.2.2.3 Voxel size, FOV and number of acquisition frames 
Voxels (3D pixels) are the building blocks that make up the reconstructed CBCT volumes. 
Smaller voxels will increase the theoretical spatial resolution and allow higher frequencies, 
smaller details, to be displayed. Smaller voxels, however, comes at the cost of radiation dose 
or image noise. With a smaller voxel, fewer photons contribute to the signal in each voxel, 
resulting in a nosier image, unless the radiation dose is increased to compensate. 
Small voxels will also require sufficient sampling of data, both ray-sampling by having 
sufficiently small detector pixel pitch and view-sampling by acquiring a sufficient number of 
image frames (or views) during the rotation. 
Using smaller voxel sizes than the data sampling rates allow, in fan direction or cone 
direction, will result in artifacts. At small amounts of under-sampling these artifacts will not 
be as noticeable and might not adversely affect diagnostics; it is common for CT to operate 
bellow the required sampling rate.6 However, the artifacts will become progressively worse 
with increased under-sampling. 
Increasing the FOV will theoretically affect the image quality negatively in CBCT due to an 
increase of scattered radiation causing noise in the image. What’s probably more important, 
however, is that an increase in FOV height results in an increased cone angle. This will 
negatively affect the resolution in parts of the reconstructed image where the x-ray beam 
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angle is higher. In practice, CBCT devices will often allow smaller voxel sizes when a 
smaller FOV is employed. 
1.3 DOSIMETRY 
The central element of dosimetry is that radiation dose is not measured directly. What we 
mean by “measuring dose” is that our radiation detectors measure one quantity, usually 
charge, and this is in turn related to a dosimetric quantity. The term radiation dose is, 
however, often haphazardly applied to many related but different quantities. Further 
increasing the complexity is the fact that dose is determined to specific materials; dose to air 
is not the same as dose to water, dose to lung tissue is a different quantity than dose to 
muscle.  
1.3.1 Dosimetric quantities 
1.3.1.1 Kerma and absorbed dose 
Two basic concepts in dosimetry are kerma and absorbed dose. Kerma is defined as the 
energy transferred from uncharged particles (such as x-ray photons) to charged particles 
(such as electrons) inside a sample, divided by the mass of this sample. Absorbed dose is in 
turn defined as the energy imparted to a sample, divided by the mass. The concept is 
illustrated in Figure 4, where a photon (hν) interacts with the mass inside the volume (V) and 
transfers its energy to an electron (e-). The distinction is that kerma does not account for any 
radiative losses carried by charged particles, in this case, energy carried outside the volume 
by electrons in the form of kinetic energy. Absorbed dose on the other hand only includes the 
energy imparted, i.e., the energy remaining inside the volume. In the special case where there 
are no radiative losses, absorbed dose is equal to kerma (Figure 5).  
 
Figure 4 Illustration of the kerma and the absorbed dose inside the volume V, in the case of some energy leaving 
volume as kinetic energy.  
 
Kerma to V: 
K = 
𝜖𝑡𝑟
𝑚𝑉
 
Dose to V: 
D = K - 
𝑟𝑎𝑑𝑖𝑎𝑡𝑖𝑣𝑒 𝑙𝑜𝑠𝑠𝑒𝑠
𝑚𝑉
    
Kerma 
hν 
𝑒− 
Energy 
transfered 
hν 
𝑒− 
Energy 
imparted 
Absorbed dose 
V V 
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Figure 5 In the special case of no radiative losses, the absorbed dose becomes equal to the kerma. 
In practice, the same conditions will be achieved if any energy leaving the volume carried by 
charged particles is matched by an equal addition from outside the volume, so-called charged 
particle equilibrium (CPE). In an x-ray field, assuming negligible photon attenuation over 
distances at the scale of the maximum range of the electrons, CPE will be achieved at the 
maximum electron range from any interfaces between different materials (Figure 6).  
 
Figure 6 The volume Vbig consists of homogenous matter, surrounded by another material. CPE will be achieved 
within the smaller volume vsmall, defined by the maximum electron range. 
This means that the absorbed dose and kerma will differ close to the interfaces between 
materials, with the difference gradually decreasing with distance from the interfaces (Figure 
7). The range of these interface effects will increase with photon energy, with diagnostic x-
ray energies resulting in about a hundred micrometer range.7  
Kerma to V: 
K = 
𝜖𝑡𝑟
𝑚𝑉
 
Dose to V: 
D = K 
Kerma 
hν 
𝑒− 
Energy 
transfered 
hν 
𝑒− 
Energy 
imparted 
Absorbed dose 
V V 
𝑉𝑏𝑖𝑔 
𝑣𝑠𝑚𝑎𝑙𝑙  
𝑒− max range 
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Figure 7 Relative difference between kerma and absorbed dose. Normalized to the kerma at the current depth in 
water. 
The assumption of CPE is important in diagnostic x-ray dosimetry since it means that the 
absorbed dose is proportional to the mass-energy absorption coefficient of a material: (?̅?𝑒𝑛 𝜌⁄ ). 
This allows us to convert dose to different materials by the mass-energy absorption 
coefficient ratio between the two materials: (?̅?𝑒𝑛 𝜌⁄ )𝑚𝑎𝑡1
𝑚𝑎𝑡2. 
1.3.1.2 Effective dose 
Absorbed dose is a purely physical concept and is limited in that it has no direct relation to 
the risk of radiation-induced harm. The concept of effective dose was introduced by the ICRP 
to compare delayed radiation risk from different kinds of irradiations of humans. Effective 
dose is defined as the sum of the mean organ dose for certain tissues at risk, multiplied by a 
weighting factor related to the relative “radiation sensitivity” of the tissue in question 
(Equation 1). The latest tissue weighting factors were published in IRCP 103 in 2007 (Table 
1).8 
𝐸 =  ∑ 𝐻𝑡 ∙ 𝑤𝑡𝑡     (1) 
 
Table 1 Tissue weighting factors for effective dose. 
Tissue wt 
Red bone-marrow, Colon, Lung, Stomach, Breast 0.12 each 
Gonads 0.08 each 
Urinary bladder, Esophagus, Liver, Thyroid 0.04 each 
Endosteum (Bone surface), Brain, Salivary glands, Skin 0.01 each 
Remaining tissues:  
Adrenals, extrathoracic airways, gall bladder, heart, kidney, 
lymphatic nodes, muscle, oral mucosa, pancreas, prostate, 
small intestine, spleen, thymus, uterus 
0.12 combined 
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It is essential to remember that effective dose is not defined for individuals, but for the entire 
population. Effective dose was introduced as a legal quantity to allow the setting of dose 
limits and to have a quantity to optimize when planning radiation protection.8 It should never 
be quantify individual risk, or even quantify risk for subgroups of the population, such as 
specific age groups. There is also a lack of scientific evidence on how inhomogeneous 
irradiation of tissue, e.g. the active bone marrow during a head CT examination, will affect 
the radiation risk. However, even with all the disclaimers and uncertainties involved in 
effective dose it is still a useful tool when comparing different radiological examinations. 
“Effective dose can be of value for comparing doses from different diagnostic procedures and 
for comparing the use of similar technologies and procedures in different hospitals and 
countries as well as the use of different technologies for the same medical examination.”8 
However, when comparing similar examinations of the same area, ICRP103 recommends the 
use of dose indexes instead of effective dose to avoid introducing unnecessary uncertainties.  
1.3.1.3 Dose indexes 
Dose indexes are defined to quantify the radiation output from an x-ray device in a way that 
is easy to measure. In the case of medical CT there are two important indexes CTDI and 
DLP, and in radiography, intervention, panoramic and CBCT there are DAP.9 
DAP is defined as the mean air kerma inside the x-ray field, multiplied with the area of the x-
ray field at the same distance (Figure 8). While the radiation dose will decrease with distance 
from the x-ray source due to geometric dispersion, the DAP will remain identical if the 
attenuation in air is negligible. Therefore, the DAP can easily be measured by a transmission 
ionization chamber placed at the x-ray tube side.  
 
Figure 8 DAP is calculated from the product of the mean air kerma and the area of an x-ray field. 
For these relatively easily measurable dose indexes, conversion factors to effective dose can 
be determined by measuring or simulating the effective dose under certain conditions and 
relating the dose index to effective dose under these conditions.10  
1.3.2 Organ dosimetry 
To determine the effective dose, the mean organ dose must be determined for the organs of 
interest, which presents two problems: determining the dose to the organ at certain points and 
estimating the mean dose through the organ from these sampling points.  
The radiation detector will not be made of the same material as the organ tissue, thus the dose 
will need to be converted using appropriate conversion factors. In practice, theoretical 
radiological surrogate tissues, defined to estimate the properties of real organ tissue, will be 
Dose 
3 mGy 
Area 
5 cm2 
DAP 
15 mGycm2 
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used, such as the ones defined by the International Commission on Radiation Units and 
Measurements.9  
For most organs, CPE can be assumed at diagnostic energies; the tissue can be assumed to be 
reasonable homogenous on the 100 µm scale relevant for the interface effects. Thus, mass-
energy absorption ratios, published for commonly used surrogate tissues, can be used to 
determine the dose.11 However, the skeletal tissues are an exception; inside the trabecular 
bone the assumption of CPE breaks down due to a significant electron contribution from the 
bone into the marrow cavities, thus increasing the dose to the active marrow and the 
osteoprogenitor cells.12 
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2 STUDY SPECIFIC AIMS 
Study I  Would CBCT examinations of the temporomandibular joint reduce the 
effective dose as compared to MDCT examinations?  (SEDENTEXCT 4.4.6) 
Study II Determining the effective dose from CBCT examinations and from 
conventional 2D radiographic examinations on maxillary impacted canines. 
Study III Determining the dose optimization potential of applying the segmentation 
(collimation) function in panoramic radiography and its possible clinical 
applications. 
Study IV Determining the effective dose from the different dental examination protocols 
on the Newtom 5G CBCT device. 
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3 METHODS AND MATERIALS 
3.1 X-RAY DEVICES AND PHANTOMS 
3.1.1 Study I 
Two x-ray devices were investigated, a Promax 3D (Planmeca Oy, Helsinki, Finland) CBCT 
and a Lightspeed VCT (GE healthcare, Chicago, USA) MDCT. The Promax 3D was operated 
at 90kV tube current (8.0 mm Al HVL) and the Lightspeed VCT was operated at 120kV (6.4 
mm Al HVL).  
Two anthropomorphic phantoms were used. Phantom 1, used for dosimetric measurements, 
was a sliced Alderson Rando dosimetric phantom consisting of a human dry skull inside 
tissue-equivalent plastic. Phantom 2, used for dose and image quality optimization, was a 
non-sliced phantom consisting of a human dry skull inside tissue-equivalent plastic. 
61 measurement points were used throughout phantom 1, chosen to correspond to the organs 
expected to contribute the most to the effective dose. Two TLDs were positioned at each 
measurement point.  
3.1.2 Study II 
Four x-ray devices were investigated including two CBCTs, a Promax 3D operating at 90 kV 
(8.0 mm Al HVL) and a Newtom 5G (QR, Verona, Italy) operating at 110 kV (4.4 mm Al 
HVL), one panoramic x-ray: Promax 2D (Planmeca Oy) operating at 62 kV (2.9 mm Al 
HVL) and one intraoral x-ray: Prostyle Intra (Planmeca Oy) operating at 66 kV (2.1 mm Al 
HVL).  
An anthropomorphic 10-year child phantom ATOM-706-C (CIRS, Norfolk, USA), made of 
tissue-equivalent plastic, was employed. 
For TLD measurements on the CBCT devices 34 measurement points were used throughout 
the phantom. Two TLDs were positioned at each measurement point.  
3.1.3 Study III 
One panoramic x-ray device was investigated: Promax 2D (Planmeca Oy). All exposures 
were performed at 66 kV tube potential (3.4 mm Al HVL) and 8 mA tube current. One sliced 
anthropomorphic Alderson Rando phantom was used. 20 measurement points was used 
thought the phantom, with one MOSFET-detector placed at each point. 
3.1.4 Study IV 
One CBCT device was investigated Newtom 5G (QR) operating at 110 kV (4.4 mm Al 
HVL). One sliced anthropomorphic Alderson Rando phantom was used. 20 measurement 
points was used thought the phantom, with one MOSFET-detector placed at each point.  
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3.2 APPLIED DOSIMETRY (STUDY I-IV) 
Effective dose was determined to allow dose comparison between different x-ray modalities. 
The effective dose was calculated according to ICRP 103.8 Tissue weighting factors from 
ICRP 103 are shown in Table 1. For the 13 “remainder” organs a weighing factor of 0.12/13 
was used. Dose to organs outside the head and neck area was considered negligible and 
assumed to be zero. The same assumption was, in study I and II, done for organs estimated to 
contribute less than 1% to the resulting effective doses: skin and muscle.  
Several organs of interest were only partly positioned inside the head and neck area. In these 
cases, the dose outside the head and neck area were assumed to be zero. The measured organ 
dose was then multiplied with the fraction of the organ inside the investigated area, in order 
to obtain the mean organ dose for the entire organ.  
In study I and IV the following organ fractions for an adult male were used.  
From Cristy, active marrow: cranium 7.6%, mandible 0.8% and cervical vertebrae 3.9%.13  
From the ICRP reference computational phantom: the osteoprogenitor cells (TM50) cranium 
16.3%, mandible 0.4%, cervical vertebrae 2.1%; lymphatic nodes 6.3%; muscle 4.2%.14 The 
fraction for esophagus was estimated to 10% and for skin to 5%, in the tradition started by 
Ludlow et al.15 
In study III the following fractions for an adult male were used. 
According to White and Rose, active marrow: cranium 11.8%, mandible 1.3% and cervical 
vertebrae 3.4%.16 The distribution of TM50 was assumed to be the same as for active 
marrow.  The fraction for esophagus was estimated to 10%, and for skin, muscle and 
lymphatic nodes to 5% in the tradition of Ludlow et al.15 
In study II the following fractions for a 10-year child was used. 
From Cristy, active marrow: cranium 11.6%, mandible 1.1% and cervical vertebrae 2.7%. No 
data on the osteoprogenitor cells were found for the appropriate age group. The fractions for 
TM50 were estimated by scaling the fractions for an adult male in the ICRP computational 
phantom with the active marrow ratio between an adult male and a 10-year child reported by 
Cristy. The resulting TM50 fractions were: cranium 24.9%, mandible 0.6%, cervical 
vertebrae 1.5%. The lymphatic node distribution for the adult male in the ICRP 
computational phantom was used: 6.3%.14 The esophagus fraction was estimated at 10% 
In study I, II and IV the dose to ICRU four-component soft tissue was used for all organs. 
Mass energy-absorption coefficient ratios from air kerma free in air to dose to water, and then 
to ICRU four-component soft tissue, were taken from the AAPM protocol for 40–300 kV x-
ray beam dosimetry.11 In study III air kerma was used for all organs of interest. In study I and 
II back-scatter factors were taken from the AAPM protocol, and in study III and IV the 
backscatter was measured as part of the detector calibration.  
In study I, dose enhancement factors (relating dose at CPE to dose under realistic electron 
contribution) were calculated for the skeletal dosimetry, based on Monte Carlo simulations 
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published by Johnson et al.12 For the Promax 3D CBCT (HVL 8.0 mm Al) this resulted in the 
following factors for active marrow: cranium 1.216, mandible 1.017, cervical vertebrae 
1.113; and the following factors for TM50: cranium 1.727, mandible 1.796, cervical 
vertebrae 1.736. For the Lightspeed VCT MDCT (HVL 6.4 mm Al) this resulted in the 
following factors for active marrow: cranium 1.192, mandible 1.014, cervical vertebrae 
1.102; and the following factors for TM50: cranium 1.671, mandible 1.747, cervical 
vertebrae 1.679. 
3.3 RADIATION DETECTORS AND CALLIBRATION (STUDY I-IV) 
3.3.1 Uncertainty estimates 
Table 2 Uncertainty estimates for a single point dosimeter measurement. 
Quantity Fractional uncertainty 
(k=1) 
Combined uncertainty 
(k=2)  
Reference 
Uncertainty for point dose measurement.  
Type B 
Nk 1.2%   
Beam quality differences 2.0%  11 
Backscatter factor 𝐵𝑤𝑎𝑡𝑒𝑟  1.5%  
11 
Pstem,air 1.0%  11 
[(?̅?𝑒𝑛 𝜌⁄ )𝑎𝑖𝑟
𝑤𝑎𝑡𝑒𝑟]𝑎𝑖𝑟  1.5%  
11 
Simultaneous calibration of several 
detectors (backscatter) 
2.0%   
Field inhomogeneities 2.0%   
(?̅?𝑒𝑛 𝜌⁄ )𝑤𝑎𝑡𝑒𝑟
𝐼𝐶𝑅𝑈 4−𝑐𝑜𝑚𝑝 𝑠𝑜𝑓𝑡 𝑡𝑖𝑠𝑠𝑢𝑒
 1.0%  
11 
Determining dose at different depths 
inside phantom 
3.0%  11 
Energy dependence 2.0%  17,18,19 
MOSFET angular dependence 5.0%  20 
TLD combined  11.5%  
MOSFET combined  15.2%  
Type A (𝑠 √𝑁⁄ )    
TLD negligible   
MOSFET About 3% to 50%   
The uncertainty in a single measurement is comprised of several elements due to the 
calibration process and dosimeter properties. Estimated components and combined standard 
uncertainties are shown in Table 2. The combined fractional uncertainty is calculated 
according to Equation 2. 
∆𝐷
𝐷
= √∑ (
∆𝑥𝑖
𝑥𝑖
)
2
𝑖     (2) 
The mean organ dose is given by Equation 3, where N is the number of measurement points. 
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𝐻𝑡 =
1
𝑁
∑ 𝐷𝑖
𝑁
𝑖     (3) 
Not all Type B uncertainties can be assumed to be independent between measurement points. 
However, even if the assume complete correlation the fractional uncertainty in the mean 
organ dose is at most equal to the fractional uncertainty in the individual measurement point, 
assuming negligible type A error (Equation 4). 
∆𝐻𝑡
𝐻𝑡
≤ √
1
𝑁
∑ (
∆𝐷𝑖
𝐷𝑖
)
2
𝑁
𝑖 =
∆𝐷
𝐷
    (4) 
This would be an overestimation of the uncertainty, since not all of the type B errors are 
correlated. Though, even with this overestimation other, independent, errors will completely 
dominate the uncertainty of the mean organ dose. In the MOSFET measurements, we have 
large type B errors due to low detector signal, especially in study III.  
However, in both the TLD and MOSFET the dominant uncertainties of the mean organ doses 
relate to how well the measured point doses are representative of the organ doses. These 
uncertainties arise from difficulties in accurately estimating the organ shape, and evenly 
covering the organ mass with measurement points. For organs completely inside the x-ray 
field these uncertainties are of manageable size. For organs partially or completely outside the 
x-ray field, these uncertainties become worse, due to significant dose gradients.21 This 
problem is further exacerbated if the number of measurement points is low in regards to the 
organ size. 
The magnitude of these uncertainties is hard to accurately estimate. To represent the 
uncertainty at an adequate number of measurement points, the estimates by Martin are used 
for organs inside and outside the x-ray field.21 For the MOSFET measurement additional 
uncertainty factors were included, due to the low number of measurement points (20). These 
were estimated based on results by Pauwels et al., who compared organ dose measurements 
in the head-and-neck area with 150 measurement points and 24 measurement points.22 The 
estimated combined standard uncertainties in organ dose are shown in Table 3.  
TLD measurements with many measurement points have been shown to agree well with MC 
simulations with voxelized phantoms; Ernst et al. obtained the following standard deviations 
between organ dose measured from 73 TLD measurement points and MC simulated organ 
dose: 3.7% at 4×4 cm FOV,  3.4% at 8×5 cm FOV and 5.1% at 14×10 cm FOV.23 The 61 
measurement points inside an adult phantom in study I and 34 inside a 10-year child phantom 
in study II are assumed to be sufficient, and no additional uncertainty estimate is employed. 
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Table 3 Uncertainty in mean organ dose, assuming a 5.7% correlated error for TLD and film, and 7.6% 
correlated error for MOSFET (k=1). 
Quantity Fractional uncertainty 
(k=1) 
Combined uncertainty 
(k=2)  
Reference 
Uncertainties in mean organ dose.    
Film scanner 2.0%  24 
Positioning, measurement points and 
organs shape: almost completely inside x-
ray field 
15% 32% 
 
21 
Positioning, measurement points and 
organs shape: partly or completely outside 
x-ray field 
40% 81% 21 
Additional error: Few measurement 
points, study III (panoramic) 
60% 145%  
Additional error: Few measurement 
points, study IV (CBCT) 
25% 95%  
Due to the small x-ray field size, all organs are considered partially or completely outside the 
x-ray field. The uncertainty in effective dose calculated according to equation 5. For 
MOSFET measurements the type B error was determined and included in the uncertainty 
calculation. 
∆𝐸 = √∑ (𝐻𝑡 ∙ 𝑤𝑡 ∙
∆𝐻𝑡
𝐻𝑡
)
2
organs
𝑡    (5) 
3.3.2 Thermoluminescent dosimeters  
LiF:Mg TLD-100 equivalent dosimeters were used in study I and II. The dosimeters were 
cross-calibrated at an accredited dosimetry laboratory in accordance with the in-air method 
from the AAPM protocol for 40–300 kV x-ray beam dosimetry, against an ion chamber 
calibrated at the Swedish secondary standard laboratory.11  
The lowest signal was about 10 times higher than the background, making the type B errors 
negligible.  
3.3.3 Dosimetric film 
Gafchromic-QR2 dosimetric film (International Specialty Products, Wayne, USA) was used 
in study II. The film was calibrated in the same manner as the TLDs. However, due to the 
non-linear dose response of film, signal-to-dose calibration curves were determined for each 
x-ray spectrum. This calibration was applied on a pixel by pixel basis on the scanned film.  
3.3.4 MOSFET dosimeters  
A TN-RD-70-W20 MOSFET device (Best Medical Canada, Ottawa, Canada) was used 
during study II and IV. The calibration process and characterisation of dosimetric properties 
have been described in-depth in a series of articles.18,20,25 The MOSFET detectors were cross 
calibrated against an ion chamber calibrated at the Finnish secondary standard laboratory. 
The cross-calibration was performed device with an x-ray device with 2.5 mm Al total 
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filtration. At these conditions, the energy dependence was confirmed to be very small.18 The 
MOSFET detectors have a noticeable angular dependence free in air: down to 67% dose 
response at the extreme for axial rotations, with a standard deviation from the mean dose 
responce of 12%.20 In-phantom measurements showed a much lower angular dependence: 
5% standard deviation and 85% as the lowest dose response. The influence of the angular 
dependence was reduced by correcting the detector signal with the mean dose response over 
the irradiated angles.  
In study IV each exposure was repeated six times, with readout after each exposure. In study 
III each exposure was repeated 10 times, with readout after each exposure. 
3.3.5 DAP measurements 
During all measurements, independent DAP measurements were obtained using external 
DAP-meters mounted at the x-ray tube side and corrected for temperature and pressure. In 
cases where effective dose was determined at several exposure levels but the x-ray spectra, 
FOV and positioning were kept constant (i.e. study I and IV), organ dose measurements were 
only performed at one exposure level. The effective dose at the other exposure levels was 
calculated by scaling the effective dose with the DAP-ratio between the exposure in question 
and the organ dose measurement. 
3.4 OPTIMIZATION OF DOSE AND IMAGE QUALITY (STUDY I & III) 
3.4.1 Exposure level (study I) 
In order to optimize the dose/image quality of the CBCT and MDCT examination, an 
observer study was conducted at several dose levels. Images were acquired at five different 
dose levels for both x-ray devices, by changing the tube current setting. All other parameters 
were kept constant. For the CBCT the tube current settings were between 4 mA and 12 mA in 
intervals of 2 mA. Pre-optimization tube current settings were 12 mA for the CBCT, the 
highest possible setting. For the MDCT the tube current settings were between 50 mA and 90 
mA in steps of 10 mA, with the pre-optimization setting being 73 mA.  
The observers consisted of four specialists in dento-maxillofacial radiology with experience 
of both CBCT and MDCT images. Four different image quality were defined: how well the 
intra-articulate joint space could be defined, the definition of the cortical bone, the definition 
of the trabecular bone and the subjective noise level. Each observer also rated their overall 
impression of the image quality.  
Each criterion was rated on a scale from 1-3, where 1 = unacceptable, 2 = acceptable, 3 = 
excellent. The optimized exposure level was defined as the lowest dose where all four 
observers rated all four criteria as at least acceptable. 
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3.4.2 Image size (study III) 
Reducing the size of the imaged and therefore irradiated area is one of the most effective 
ways of reducing the dose. This is often applied in dental CBCT but not extensively used in 
panoramic radiology.26 In most cases a smaller image size is available for children,27 
however, some panoramic devices, such as the Promax 2D, have more options to restrict the 
image size further. In the case of Promax 2D the user has the option to collimate the x-ray 
field further and remove several image segments to customize the image size. Ten possible 
collimations were investigated (Figure 9). 
To investigate the clinical applicability of reduced image size in panoramic radiographs a 
retrospective study was performed on 252 patient cases. All referrals to our university clinic 
during a three-month period with patients aged 18 and above were included, if the patient had 
a panoramic image taken during this three-month period or within one year prior.  
Based on the diagnostic question in the referral, one specialist in dento-maxillofacial 
radiology (DB) categorized each case in accordance with the smallest suitable collimation. 
Each case was also categorized according to the clinical indication for the referral. 
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Figure 9 The 10 different collimations investigated in the study and a panoramic radiograph of the phantom with 
MOSFET and lead cables visible. The numbered squares show the position of the segments which may be 
removed. Image from study III. 
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4 STUDY RESULTS AND DISCUSSIONS 
4.1 STUDY I 
4.1.1 Results 
4.1.1.1 Dose optimization 
The optimized tube current level for the CBCT was 6mA, half of the pre-optimization level. 
For the MDCT the optimized mA level was 80mA, close to the pre-optimization level of 73 
mA. Figure 10 shows the distribution of the observer ratings on overall image quality at 
different exposure levels. 
 
Figure 10 Observer rating of overall image quality (from study I). 1 = unacceptable, 2 = acceptable, 3 = excellent 
4.1.1.2 Dosimetry 
Pre-optimization, a bilateral CBCT-examination of the TMJ resulted in about 60% higher 
effective dose compared to the MDCT (Table 4). After optimization, this had been reversed, 
with MDCT resulting in a 35% higher effective dose than the bilateral CBCT examination 
(Table 5). The relative contribution to effective dose from the different organs is shown in 
Figure 11 and Figure 12. The expanded (k=2) relative uncertainty in the effective dose was 
35% for CBCT and 34% for MDCT. The difference in effective dose for the optimized 
examinations was not significant at the 95% confidence level.  
Table 4 Pre-optimization effective dose ± standard uncertainty (k=1), dose index and HVL for bilateral and 
unilateral TMJ-examinations. 
Device and 
examination 
Scan 
length/FOV  
Effective dose 
[µSv] 
DAP  
[Gycm2] 
CTDIvol  
[mGy] 
DLP 
[mGycm] 
HVL 
[mm Al] 
Lightspeed VCT 
bilateral TMJ 
3 cm 113 ± 19 - 7.42 38.2 6.4 
Promax 3D 
unilateral TMJ 
4 × 5 cm 92 ± 16 0.606 - - 8.0 
Promax 3D 
bilateral TMJ 
4 × 5 cm × 2 184 ± 32 1.21 - - 8.0 
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Table 5 Post-optimization effective dose ± standard uncertainty (k=1), dose index and HVL for bilateral and 
unilateral TMJ-examinations 
Device and 
examination 
Scan 
length/FOV  
Effective dose 
[µSv] 
DAP  
[Gycm2] 
CTDIvol  
[mGy] 
DLP 
[mGycm] 
HVL 
[mm Al] 
Lightspeed VCT 
bilateral TMJ 
3 cm 124 ± 21 - 8.13 41.9 6.4 
Promax 3D 
unilateral TMJ 
4 × 5 cm 46 ± 8 0.303 - - 8.0 
Promax 3D 
bilateral TMJ 
4 × 5 cm × 2 92 ± 16 0.606 - - 8.0 
 
 
Figure 11 Relative contribution to the resulting effective dose from different organs for the Promax 3D 
examinations. 
 
Figure 12 Relative contribution to the resulting effective dose from different organs for the Lightspeed VCT 
examination. 
Active Marrow 28.1%
Endosteum 6.2%
Brain 11.1%
Extrathoracic 
Airways 13.7%
Lymphatic nodes
1.2%
Oral Mucosa 7.2%
Salivary glands 24.0%
Thyroidea 8.0%
Esophagus 0.7%
Promax 3D
Active Marrow 25.4%
Endosteum 5.5%
Brain 11.5%
Extrathoracic Airways 19.2%
Lymphatic nodes
0.8%
Oral Mucosa 13.7%
Salivary 
glands 14.9%
Thyroidea 8.3% Esophagus 0.7%
Lightspeed VCT
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4.1.2 Discussion 
4.1.2.1 Dose optimization 
The dose optimization performed in this study is relatively basic, only using a single phantom 
and only altering a single parameter, tube current. The optimization could be improved in 
several ways such as using patient cases or investigating other parameters such as tube 
voltage. The main reasons for the study design were, in the case of avoiding patient 
examinations, ethical considerations in exposing patients to multiple unnecessary 
examinations and, in the case of only investigating the tube current, to allow the effective 
dose to be easily scalable from the TLD measurements.  
The resulting optimization method is a pragmatic and relatively quick method that could be 
used routinely to optimize new equipment for different examinations and diagnostic tasks. 
The lack of patient images would necessitate a follow-up period, in which the clinical cases 
are evaluated to ensure that the optimized exposure settings are appropriate under clinical 
conditions. The resulting decrease in dose from the CBCT examination, down to 50% from 
the factory preset, highlights the importance of optimization by the user as well as the 
importance for the manufacturer to allow the user to manually adjust exposure settings. Both 
these aspects and their importance have been emphasized in the SEDENTEXCT guidelines.28 
Regarding optimization of the tube voltage, user optimization of this settings was not 
considered as important as tube current optimization. In dentomaxillofacial CBCT higher kV 
are generally considered to give better image quality per x-ray dose. E.g. Pauwels et al. have 
shown an improvement in CNR with the increase of kV for a 3.1 mm al total filtration CBCT 
device, with the highest CNR obtained at the maximum setting of 90 kV (3.2 mm Al HVL).29 
Lofthag-Hansen et al. have also shown a general tendency of higher tube voltage providing 
more dose efficient CBCT examinations.30 However, the Planmeca CBCT devices use higher 
energy then most x-ray devices, due to the very thick 0.5 mm Cu filtration. We used the 
highest tube voltage setting 90 kV, resulting in an HVL of about 8.0 mm Al. It would be of 
future interest to investigate if higher kV is advantageous even at these strongly filtrated x-ray 
beams.  
4.1.2.2 Comparison between CBCT and MDCT 
At optimized exposure levels, the Lightspeed VCT MDCT examination resulted in 35% 
higher effective dose compared to a bilateral Promax 3D CBCT examination. This small 
difference was not statistically significant. Looking at the literature there are few published 
doses from TMJ examinations with CBCT. In 2011 Librizzi et al. reported an effective dose 
550µSv for a bilateral TMJ examination with a CB MercuRay (Hitachi Medical, Twinsburgh, 
USA) and either one 9-inch FOV or two 6-inch FOVs.31 In 2013 Lukat et al. reported an 
effective dose of 220µSv for an examination with a CB MercuRay and 9-inch FOV, and an 
effective dose of 20µSv for two 5.0 × 3.7 cm FOV with a Kodak 9000 3D (Carestream, 
Rochester, NY).32 I am not aware of any other published studies on the radiation dose from 
MDCT of the TMJ.  
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The variation in effective dose from CBCT in the literature is several times larger than the 
difference we saw between Promax 3D and Lightspeed VCT. A major part of this difference 
comes from the different FOV sizes available, with not all CBCT models offering suitable 
FOVs for TMJ diagnostics. It’s also worth noticing that two authors reported on the same 
CBCT model with drastically different radiation dose due to different exposure protocol 
employed. It is not clear if this is due to user optimization of the exposure protocols, or if the 
factory preset changed overtime. 
4.1.2.3 Bone dosimetry 
It is rare to properly correct for the interface effects in bone dosimetry. Generally, one of two 
alternatives are used: either no corrections are applied for either tissue, or no correction is 
applied to active marrow but the dose to the osteoprogenitor cells is multiplied with the mass-
energy absorption ratio for cortical bone, thus calculating the dose to a solid slab of 
mineralized bone. 
The size of the dose enhancement factors increases with energy and varies between different 
bones. Thus, the factors will vary with different examination areas and x-ray devices. 
Cranium has the highest factors of all bones and contributes a large part of the effective dose 
for head examinations. In the current study, active marrow inside the cranium contributed the 
most to effective dose of all organs: 21% and 23% for Promax 3D and Lightspeed VCT 
respectively. This percentage will be lower for dentoalveolar examinations but still major; 
Pauwels et al. reported a mean contribution of 14% from active marrow for small, medium 
and large FOV CBCT examinations, with no dose enhancement correction.22  
In study I the corrections resulted in a 19% and 16% increase in estimated active marrow 
dose for Promax 3D and Lightspeed VCT respectively, resulting in a 4.7% and 3.8% increase 
in effective dose. For TM50 the corrections resulted in an 75% dose increase for Promax 3D 
and 67% dose increase for Lightspeed VCT, resulting in an increased effective dose by 2.8% 
and 2.3% respectively. The total effect on effective dose from both active marrow and TM 
dose was 7.5% for Promax3D and 6.1% for lightspeed VCT.  
If the mass-energy absorption ratio for cortical bone had been used for TM50 instead, this 
would have resulted in an increased organ dose of 230% and an 8.8% increase in effective 
dose for Promax3D and an increased organ dose and effective dose by 270% and 9.3% 
respectively for Lightspeed VCT. 
Even in a reasonable worst-case scenario of 8% systematic underestimation of the effective 
dose, this can be considered relatively small compared to the uncertainties involved in 
determining the effective dose from measurements. Studies can be compared in terms of 
effective dose regardless of the bone dosimetry methods employed, but the differences should 
be taken into account when comparing individual organ doses.  
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4.2 STUDY II 
4.2.1 Results 
The results for each individual image are shown in Table 6.  A standard 2D examination 
could vary from a unilateral examination comprised of two periapical images with different 
projections up to a bilateral examination using three periapical images and a panoramic 
image. In the first case this would result in a combined effective dose of 1.2 µSv and in the 
latter case in 6.0 µSv. Compared to the lowest 2D examination dose a Newtom 5G 
examination would result in 140 times higher effective dose, and a Promax3D examination in 
70 times higher dose. Compared to the highest 2D examination dose a Newtom 5G 
examination would result in about 30 times higher effective dose, and a Promax3D 
examination would result in about 15 times higher effective dose. 
Table 6 Resulting effective doses with combined standard uncertainties (k=1).  
Device 
(Projection) 
Modality  Dosimeter  Image size / 
FOV [cm] 
Effective dose 
[µSv] 
DAP  
[mGycm2] 
HVL 
[mm Al] 
Promax 3D CBCT TLD 4 × 5 88 ± 15 510 8.0 
Newtom 5G CBCT TLD 6 × 6 172 ± 31 1080 4.4 
Newtom 5G  CBCT Film 6 × 6 166 ± 29 1080 4.4 
Promax 2D Panoramic Film 19.2 × 9.2 4.1 ± 0.8 21.9 2.9 
Prostyle 
(Periapical lateral) 
Intraoral 
 
Film 4.5 × 5.5 0.6 ± 0.1 7.42 2.1 
Prostyle 
(Periapical central) 
Intraoral Film 4.5 × 5.5 0.7 ± 0.2 7.42 2.1 
4.2.2 Discussion 
Marcu et al. have investigated the effective dose from pediatric examinations with a CBCT 
device in the Promax3D family.33 They employed MC simulations using voxelized pediatric 
5- and 8-year phantoms. For a maxillary canine examination on the 8-year phantom, using 
4.2 x 5.5 cm FOV, 96 kV and 96 mAs, they obtained an effective dose of 125 µSv. In order 
to compare with our 90 kV examination, the difference in radiation output were estimated by 
simulating the different x-ray spectra in the SpekCalc software by Gavin Poludniowski.34,35 
Our results, scaled to 96kV, 96 mAs and the slightly larger FOV, would correspond to about 
113 µSv. This agrees with the results by Marcu et al. within one standard uncertainty.  
In the present study, no optimization study was conducted before comparing the doses from 
the different x-ray modalities, bringing additional uncertainties to the result. For CBCT the 
highest resolution modes were used (0.16 mm for promax3D and 0.125 mm for Newtom 5G) 
and low noise levels were assumed to be required to accurately identify small resorptions. 
However, potential for dose reduction has been shown by Hidalgo Rivas et al.36 They 
investigated CBCT examinations on maxillary impacted canines to identify resorption and 
found that their radiation dose could be halved, to about 0.146 Gycm2, while maintaining a 
small voxel size of 0.08 mm. This DAP value is noticeably lower compared to the ones 
employed in study II, Newtom 5G resulted in about seven times higher dose. However, some 
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of the difference is explained by the smaller FOV of 4 × 4 cm used. Still, assuming an x-ray 
field of the same size as the nominal FOV, our dose level is about three times higher (2.9 for 
Promax 3D and 3.3 for Newtom5G). 
In reality, we do not have the option to reduce the FOV; the smallest available volume was 
used for both CBCT devices. On Promax 3D the user can manually set the tube current, but 
Newtom 5G lack the option to manually set the exposure level. In this case the user is limited 
to lowering the dose about 30% by reducing the number of acquired image frames (Study 
IV). This exemplifies that not all CBCT devices are designed to perform the full range of 
dento-maxillofacial examinations at optimized dose. 
If we were to convert the DAP for the Hidalgo Rivas optimized exposure protocol into 
effective dose, using conversion factors calculated from our results, it would result in 
between 25 µSv and 22 µSv. This is about 4 to 14 times higher than our complete 2D 
examinations. While this difference is noticeably smaller than our results, the CBCT dose is 
still significantly higher. Therefore, the recommendation would be to start with periapical 
images, and only continue with CBCT images when it is required. 
More root resorptions are detected in CBCT examinations compared to 2D examinations.37–39 
However, it is not clear if the increased detection results in significant changes in treatment 
plans. Some studies show significant differences,39,40 but some do not.38,41 Based on results 
by Christell et al. (investigating 12 patient cases, where only one had their treatment plan 
significantly changed by CBCT), it might be possible to identify selection criteria for when 
CBCT is recommended.42 However, further studies on a larger patient populations are 
required to determine evidence based selection criteria. 
4.3 STUDY III 
4.3.1 Results 
4.3.1.1 Dosimetry 
 
Figure 13 The ten different collimations investigated in the study. Image from study III. 
The imaged area of each protocol is illustrated in Figure 13. Effective doses for each protocol 
and relative dose level compared to a full field panoramic are shown in Table 7.  
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Table 7 Effective dose results ± standard uncertainty (k=1), relative dose level compared to PAN1, and measured 
DAP value for each protocol.  
Protocol 
Effective dose 
[µSv] 
Combined expanded 
uncertainty k=2 
Relative dose 
(%) 
DAP 
[mGycm2] 
PAN 1 17.6 ± 5.5 63% 100 83 
PAN 2 2.3 ± 0.7 60% 13.1 9.2 
PAN 3 7.9 ± 2.6 66% 44.9 20 
PAN 4 5.0 ± 1.7 69% 28.4 5.9 
PAN 5 10.5 ± 3.5 66% 59.7 38 
PAN 6 11.7 ± 3.6 62% 66.5 57 
PAN 7 16.8 ± 5.4 64% 95.5 56 
PAN 8 4.6 ± 1.5 64% 26.1 19 
PAN 9 4.5 ± 1.3 61% 25.6 37 
PAN 10 5.9 ± 1.9 66% 33.5 11 
4.3.1.2 Dose optimization 
In 20% of the cases a full field panoramic radiograph was deemed required (Figure 14). 
Clinical indications generally requiring a full field radiograph in case of trauma, 
orthodontic/orthognathic treatment and TMJ. Most cases, about 60%, could be performed 
with PAN5, limiting the view to the teeth and parts of the mandible and maxilla. In some 
cases, about 7%, PAN10 could be used for imaging of unilateral mandibular molar. Other 
protocols were rarely deemed suitable and only accounted for about 12% of the cases.  
 
Figure 14 Suitable collimation for each of the 252 patient cases based on the referral. Results presented as 
protocol; number of cases; percentage of total cases. 
PAN1; 52; 20%
PAN2; 2; 1%
PAN3; 12; 5%
PAN4; 0; 0%
PAN5; 153; 61%
PAN6; 1; 0%
PAN7; 5; 2%
PAN8; 2; 1%
PAN9; 8; 3% PAN10; 17; 7%
Suitable collimation
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Figure 15 Clinical indication for referral for the 252 patient cases. 
Using two collimated protocols, PAN1&5, resulted in a large DAP reduction of about 40% 
when considering the combined DAP for all patient cases included (Figure 16). Using 
additional collimated protocols showed little effect, with about 2% reduction in total DAP for 
each now protocol added from 3 to 5. Additional protocols above 5 showed no discernible 
effect. 
 
Figure 16 DAP reduction potential with increased number of collimations employed. Number of protocols: 1 
PAN1; 2 PAN5&1. 3 PAN5,1&10; 4 PAN5,1,10&3;5 PAN5,1,10,3&9; 6 PAN5,1,10,3,9&7. 
4.3.2 Discussion 
4.3.2.1 Dosimetry 
Organ dose measurements in panoramic x-ray are problematic, and the effects are clearly 
visible in this study. The choice of MOSFET dosimetry exacerbates these problems and 
results in high uncertainties. The low detector dose and the relatively low sensitivity of 
MOSFET compared to TLD, resulting in high Type A uncertainties.18  
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In regard to detector placement, there is a problem with a lack of measurement points in the 
height of the nasal cavity. This is seen in the very similar results for PAN 1 and 7; PAN 6 and 
5; and PAN 8 and 9. These results are explained by no measurement point being located in 
the phantom slice corresponding to this area. 
The low number of measurement points is a major problem in small x-ray fields.22 Due to the 
distinctive dose distribution in panoramic x-ray (Figure 17), with it’s very small high-dose 
regions this problem is expected to be even worse than for small field CBCT. The uncertainty 
introduced by sampling from point measurements in general, and so few measurement points 
specifically, is very hard to estimate. The uncertainty estimation was based on results for 
small field CBCT using 24 measurement points versus 150 measurement points published by 
Pauwels et al., with the assumption that the deviation for panoramic x-ray would have similar 
uncertainties as the worst case in CBCT.22 However, it is not obvious that even a 150 
measurement point setup would be enough, due to the extreme dose distributions in 
panoramic x-ray. In general, film dosimetry or Monte Carlo simulation are methods preferred 
for organ dose measurements for panoramic radiography. Except in cases where effective 
doses are required, due to comparison with other x-ray modalities or x-ray of other regions, 
organ dose measurement should generally be avoided in panoramic x-ray. For dose 
optimization purposes and comparisons within the modality, the dose index (DAP) should be 
used directly to avoid introducing additional uncertainties. 
DAP to E conversion factors for full field panoramic examinations, ranging from 0.087 to 
0.131 µSv/mGycm2, have been published by Loe. et al.43 In contrast, we obtained a 
conversion factor of 0.212 µSv/mGycm2. Loe et. al. used 106 TLDs, likely making their 
results more reliable than in the current study.  
 
Figure 17 Left, dose distribution in CBCT (Newtom5G), in contrast with dose distribution from panoramic, 
right.  
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4.3.2.2 Dose optimization 
Using several different collimated protocols may result in decreased patient doses. However, 
this must be judged against the possible drawback of missing important diagnostic 
information outside the imaged area. Using a larger field size than in the suitable collimated 
protocols was not considered justified since there is no indication to expect clinical findings 
outside this area. However, adding more protocols to clinical routine increases the 
complexities for the staff and increases the risk of the wrong collimation being chosen by 
mistake. This might result in patient recalls for additional examination, with additional 
radiation dose, or worse: the omission of pathology. Therefore, collimated panoramic 
examination should only be introduced as a clinical routine in cases of noticeable benefit in 
terms of the collective patient dose. 
Due to the uncertainties in determining the effective dose, DAP was used to compare the 
relative dose reduction between different collimated protocols. For the patient cases at our 
University clinic the use of two different collimations, full field (PAN1) and teeth including 
parts of the mandible and maxilla (PAN5), are recommended. The main reason for this is the 
rarity of patient cases in which other collimation protocols were deemed suitable. However, 
not all clinics have the same patient case profile, and the benefit should be judged for the 
common clinical indication at the specific clinic. E.g. one clinical indication that is likely to 
be more common in general dental clinics are examinations of mandibular molars. In these 
clinics, the inclusion of PAN10 in clinical practice might be justified. This would result in 
about 70% dose reduction for these patients, compared to PAN5. 
4.4 STUDY IV 
4.4.1 Results 
Resulting effective doses from the MOSFET measurements and DAP to E conversion factors 
are shown in Table 8. Effective doses at all available exposure settings, calculated from 
independent DAP measurements and the conversion factors mentioned above, are shown in 
Table 9.  
Table 8 Results for the MOSFET measurements of effective dose for each combination of position, resolution 
and FOV, using Regular scan mode. DAP to E conversion factors are calculated from the measured DAP and 
effective dose. Uncertainties for effective dose and conversion factor presented with k=1.  
Positioning FOV 
[cm]  
Voxel size 
[mm] 
DAP  
[Gycm2] 
Effective dose 
[µSv]  
Conversion factor  
[µSv/Gycm2] 
Maxilla front 6 × 6 0.15 (HiRes) 0.898 85.0 ± 18 95 ± 20 
Mandible 6 × 6 0.15 (HiRes) 0.967 116 ± 25 120 ± 26 
Premolar 6 × 6 0.15 (HiRes) 1.13 135 ± 30 119 ± 26 
Dentoalveolar 8 × 8 0.15 (HiRes) 1.77 209 ± 44  118 ± 25 
Dentoalveolar 8 × 8 0.30 (StdRes) 0.627 69.7 ± 15 111 ± 23 
TMJ/Ear 15 × 5 0.15 (HiRes) 2.28 185 ± 41 81 ± 18 
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For dental examinations, the lowest effective dose was 45 µSv for 8 × 8 cm FOV, standard 
resolution and Eco scan mode. The highest effective dose was 259 µSv for 8 × 8 cm FOV, 
high resolution and Enhanced scan mode. TMJ protocols ranged from 107 to 217 µSv 
depending on scan mode. The use of high-resolution mode resulted in about 2.9 times higher 
dose compared to standard resolution. The reduced view sampling of the Eco scan mode 
resulted in about 30% lower dose, while increased view sampling, Enhanced scan mode, 
resulted in about 40% higher dose compared to Regular scan mode. 
Table 9 Effective dose (± combined uncertainty k=1), calculated from DAP to E conversion factors, for all 
available exposure settings.  
FOV &  
Resolution mode 
Position Scan mode Frames DAP 
[Gycm2] 
Effective dose 
[µSv] 
6 × 6 [HiRes] Maxilla front Eco 248 0.709 67 ± 14 
6 × 6 [HiRes] Maxilla front Regular 417 0.973 92 ± 19 
6 × 6 [HiRes] Maxilla front Enhanced 501 1.43 136 ± 29 
6 × 6 [HiRes] Mandible  Eco 248 0.737 89 ± 19 
6 × 6 [HiRes] Mandible  Regular 417 1.02 122 ± 27 
6 × 6 [HiRes] Mandible  Enhanced 501 1.49 179 ± 39 
6 × 6 [HiRes] Premolar Eco 248 0.785 94 ± 20 
6 × 6 [HiRes] Premolar Regular 417 1.10 131 ± 28 
6 × 6 [HiRes] Premolar Enhanced 501 1.59 189 ± 40 
8 × 8 [HiRes] Dentoalveolar Eco 248 1.15 128 ± 27 
8 × 8 [HiRes] Dentoalveolar Regular 372 1.73 193 ± 41 
8 × 8 [HiRes] Dentoalveolar Enhanced 501 2.33 259 ± 55 
8 × 8 [StdRes] Dentoalveolar Eco 249 0.379 45 ± 9 
8 × 8 [StdRes] Dentoalveolar Regular 374 0.571 67 ± 14 
8 × 8 [StdRes] Dentoalveolar Regular +boosted 374 0.915 108 ± 22 
8 × 8 [StdRes] Dentoalveolar Enhanced 460 0.757 89 ± 18 
8 × 8 [StdRes] Dentoalveolar Enhanced +boosted 460 1.21 143 ± 30 
15 × 5 [HiRes] TMJ/Ear Eco 226 1.32 107 ± 24 
15 × 5 [HiRes] TMJ/Ear Regular 373 1.96 159 ± 35 
15 × 5 [HiRes] TMJ/Ear Enhanced 485 2.68 217 ± 48 
4.4.2 Discussion 
The DAP to E conversion factors determined showed little variation, with the exception being 
the TMJ examination and, to a lesser extent, the examination of the anterior maxilla. The 
different DAP to E conversion factor for TMJ examination compared to conversion factors 
for dental examinations is expected, considering the different irradiated regions. Therefore, 
for increased accuracy, specific conversion factors should be used for CBCT examinations of 
the TMJ or inner ear. 
There are two additional explanations for the different DAP to E conversion factor for 
anterior maxilla compared to other dental programs: a lack of measurement points and the 
volume extending outside the patient. As noted in study III, there is a lack of measurement 
points inside the cranial half of the maxilla. This may lead to an underestimation of the 
effective dose when the volume is centered in the maxilla. Secondly, when more of the 
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volume extends outside the patient, more radiation will miss the patient and not contribute to 
the effective dose. Out of these two reasons, the volume extending outside the patient is real 
and ought to be accounted for in the conversion factor, while the lack of measurement points 
in the maxilla is a measurement error. Due to the uncertainties in the measurement method, it 
cannot be determined if specific conversion factors for the anterior maxilla would improve 
the accuracy when estimating effective dose from DAP measurements. 
Stratis et al. have determined effective doses for Newtom 5G examinations of the temporal 
bone through MC simulation using the ICRP reference adult male phantom.44 Their 15 × 5 
cm FOV examination, analogous to our TMJ/ear examination, resulted in an effective dose of 
220 µSv, compared to our results of 185 and 159 µSv. Stratis et al. did not present DAP 
values but used 143 mAs resulting in 1.54 µSv per mAs, compared to our 101 mAs for 185 
µSv resulting in 1.83 µSv per mAs. Our results agreed with Stratis et al. within one standard 
uncertainty. However, using µSv per mAs to compare the studies does not account for 
potential individual variations in radiation output and x-ray field size between different 
Newtom 5G devices. 
Nardi et al. have determined effective doses for Newtom 5G though TLD measurements 
inside an Alderson Rando phantom.45 For a dentoalveolar examination with 8 × 8 cm FOV 
high-resolution and enhanced scan mode they got an effective dose of 565 µSv and 1.01 
Gycm2 DAP, resulting in a conversion factor of 560 µSv/Gycm2. For an inner ear protocol 
with 15 × 5 cm FOV high-resolution and enhanced scan mode they got an effective dose of 
361 µSv and 1.84 Gycm2 DAP, resulting in a conversion factor of 200 µSv/Gycm2. These 
results cannot be considered reliable; the 560 µSv/Gycm2 was significantly higher than all 
other published results (see section 6.1.2, Table 11), indicating problems with either the 
CBCT device employed or the dosimetric method. The large difference in DAP compared to 
our results could be explained by the use of nominal DAP displayed by the CBCT device 
without independent verification measurements. The Newtom 5G DAP calibration method 
systematically underestimates the DAP, often by 50 to 100%.a This underestimation, 
however, is unlikely to completely explain the resulting conversion factors. 
                                                 
a Private communication QR. 
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5 STUDY CONCLUSIONS 
5.1 STUDY I 
• No significant difference was seen in the effective dose from optimized TMJ 
examinations with Promax 3D and Lightspeed VCT. 
• The difference in effetive dose from TMJ-examinations with CBCT and MDCT is 
small compared to the variation within published CBCT doses. 
• User optimization of factory preset examination protocols is more important than the 
choice between CBCT and MDCT. 
• The availablily of a suitable FOV is essential for optimized CBCT-examinations. 
Either a large radius and small height volume for bilateral TMJ or small radius and 
height for unilateral TMJ. 
• Not correcting for bone interface effects leads to an underestimation of the effective 
dose of up to about 8%. For dentoaveolar examinaitons this underestimation will be 
less pronounced.  
5.2 STUDY II 
• The difference in effective dose from CBCT compared to 2D examination ranged 
from 15 times to 140 times higher. 
• Low dose CBCT protocols from the literature resulted in about 4 to 14 times higher 
dose compared to our 2D examinations. 
• It is recommended to start with periaphical radiographs and only continue with CBCT 
when deemed necesarry. 
• Some CBCT models do not allow for optimized examination protocols for the maxilla 
in children. 
5.3 STUDY III 
• The inclusion of collimated panoramic radiograhps, limited to the teeth and parts of 
the mandible and maxilla, in clinical practice in addition to full field panoramic 
radiographs is recommended. This would lead to a reduction in collective patient dose 
from panoramic radiographs of about 40% at our university clinic. 
• Other collimated protocols were not recommended at our university clinic, due to the 
low number of applicable patient cases. 
• The inclusion of a specific collimation for mandibular molar examinations would be 
recommended at clinics with a large number of molar examinations, due to a 70% 
dose reduction compared to a panoramic radiograph of all teeth. 
• Due to highly inhomogenius dose distributions, MOSFET-dosimetry is not 
recommended for panoramic x-ray. 
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5.4 STUDY IV 
• Effective doses for dental and TMJ examinations ranged from 45 µSv to 259 µSv. 
• High-resolution mode resulted in about 2.9 times higer dose than corresponing 
standard-resolution examinations. 
• DAP to E conversions factors were: 120 µSv/Gycm2 for dentoalveolar, mandibular 
and premolar examinations; 95 µSv/Gycm2 for examinaitons of the anterior maxilla; 
81 µSv/Gycm2 for examinations of the TMJ or inner ear. 
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6 GENERAL DISCUSSIONS 
6.1 GENERALISATION 
Since the introduction of dentomaxillofacial CBCT many studies have determined effective 
doses through measurements or computer simulations.46,47 These studies have investigated 
many different combinations of CBCT models, exposure settings, FOV and position. Of great 
benefit to the field would be the ability to generalize these results and make them applicable 
to future CBCT models, thus limiting the need for time consuming investigations. In their 
review of the field, Al-Okshi et al. failed to generalize effective doses, concluding that most 
studies lacked the necessary description of relevant parameters to allow comparison between 
studies.46 Al-Okshi et al. lists 17 parameters to describe the CBCT examination, dosimeter 
and phantom.  
I would propose a slightly different list of essential parameters required when investigating 
patient dose, disregarding image quality aspects. In terms of CBCT device and examination: 
HVL (or tube voltage and filtration), DAP (independently measured), FOV, angle of rotation 
and positioning. The dosimetric method, calibration and phantom should also be described in 
sufficient detail to enable the reader to estimate any systematic or random errors. 
6.1.1 Uncertainties in patient dosimetry 
Based on the estimates employed in this thesis, the standard uncertainty in effective dose for 
measurements with 20-30 measurement points in adult anthropomorphic phantoms were 
about 22% for medium FOV (between 5 × 5 cm and 10 × 10 cm) CBCT examinations. MC 
simulation with geometric phantoms, such as PCXMC, is estimated to have similar 
uncertainties as above.48 For small FOV (≤ 5 × 5 cm), if an additional uncertainty in organ 
dose of 40% is assumed (see section 3.3.1 Uncertainty estimates), the resulting combined 
uncertainty would be about 25%. 
Corresponding measurements with “sufficient” measurement points were assumed a standard 
uncertainty of about 17%. TLD measurements with 71 measurement points have shown good 
agreement with MC simulations in voxelized phantoms,23 while 24 measurement points have 
been shown insufficient for small FOV.22 Based on this and practical experience during this 
thesis, at least 50 measurement points, efficiently used, would be required for the number of 
measurement points to be deemed sufficient. 
The most accurate estimates of effective dose would logically come from MC simulations 
using the two ICRP reference phantoms. With the use of official reference phantoms, 
uncertainties due to differences between individual phantoms can be removed. The 
uncertainty is assumed to be less than for non-reference phantoms and a rough estimate of 
12% used. 
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Table 10 General uncertainty estimates for the effective dose determined though different methods. 
Method Estimated uncertainty in E (k=1) 
Point dose measurements. N < 50. Small FOV 25% 
MC in geometric phantoms. Small FOV 25% 
Point dose measurements. N < 50. Medium FOV 22% 
MC in geometric phantoms. Medium FOV 22% 
Point dose measurements. N ≥ 50 17% 
Film measurements 17% 
MC in voxelized phantoms 17% 
MC in ICRP reference phantoms 12% 
The uncertainties presented in this thesis are realistic estimates based on published results. 
However, due to a lack of data in the literature, these estimates are themselves uncertain. It 
would be of future interest to examine the uncertainties closer, preferably through MC 
simulation in ICRP reference phantoms. 
6.1.2 Effective dose conversion factors 
The use of DAP to E conversion factors in dentomaxillofacial CBCT have been criticized by 
some authors, such as Ludlow.47 One argument put forth against this methodology is that the 
relation between DAP and effective dose varies with the positioning of the examined area. 
Therefore, the use of a common DAP to E conversion factor for the entire range dento-
maxillofacial examinations is not realistic. However, neither is this necessary. 
The parameters causing the variation in DAP to E conversion factors need to be identified, 
and specific conversion factors determined for each set of parameters. For the concept of 
conversion factors to be practically applicable, the number of parameters should be kept low 
to avoid an unmanage amount of different conversion factors.  
Some published studies on the patient dose from CBCT presents the DAP values, but many 
omit this information. Based on the data in the literature, some examples of position specific 
DAP to E conversion factors are shown in Table 11 and Table 12. Uncertainties are estimated 
based on Table 10.  
Some trends can be inferred from the data, e.g. examinations using a half rotation consistently 
produce higher DAP to E conversion factors than corresponding examinations using full 
rotations. While the size of the FOV seem to affect the conversion factors, this variation is 
relatively minor considering the uncertainties. The x-ray energy may have a large effect on 
the conversion factor, but there are insufficient data to draw any conclusion. 
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Table 11 DAP to E conversion factors (𝑪𝑫𝑨𝑷
𝑬 ) for dentoalveolar examinations, calculated from different sources in 
the literature. Conversion factors followed by * denotes the use of nominal DAP displayed by the device. HVL 
followed by * denotes a value either taken from other sources or estimated from the tube voltage and filtration. 
𝑪𝑫𝑨𝑷
𝑬  
[µSv/ 
Gycm2] 
 
Uncertainty 
[k=2] 
FOV 
[cm] 
HVL 
[mm Al] Angle Method 
MC-phantom/ 
Nbr. of points CBCT model Source 
120 ± 29 16 × 13 4.2* 360 MC ICRP  i-Cat Next Gen Morant et al.49 
130 ± 31 16 × 13 4.2* 180 MC ICRP i-Cat Next Gen Morant et al. 
120 ± 29 16 × 11 4.2* 360 MC ICRP i-Cat Next Gen Morant et al. 
140 ± 34 16 × 11 4.2* 180 MC ICRP i-Cat Next Gen Morant et al. 
130 ± 31 16 × 10 4.2* 360 MC ICRP i-Cat Next Gen Morant et al. 
140 ± 34 16 × 10 4.2* 180 MC ICRP i-Cat Next Gen Morant et al. 
130 ± 31 16 × 8 4.2* 360 MC ICRP i-Cat Next Gen Morant et al. 
150 ± 36 16 × 8 4.2* 180 MC ICRP i-Cat Next Gen Morant et al. 
140 ± 34 8 × 8 4.2* 360 MC ICRP i-Cat Next Gen Morant et al. 
180 ± 43 8 × 8 4.2* 180 MC ICRP i-Cat Next Gen Morant et al. 
120 ± 52 8 × 8 4.4 360 MOSFET 20 Newtom 5G Study III 
110 ± 49 8 × 8 4.4 360 MOSFET 20 Newtom 5G Study III 
560* ± 246 8 × 8 4.4* 360 TLD 33 Newtom 5G Nardi et al.45 
460* ± 202 12 × 8 4.4* 360 TLD 33 Newtom 5G Nardi et al. 
270 ± 117 8 × 8 7.7 200 MOSFET 20 Promax3D Koivisto et al.48 
230 ± 100 8 × 8 7.7 200 MC Geometric Promax3D Koivisto et al. 
120* ± 41 14 × 10 3.96 360 TLD 71 Accuitomo 170 Ernst et al.23  
110* ± 37 14 × 10 3.96 360 MC Voxelized  Accuitomo 170 Ernst et al. 
 
Table 12 DAP to E conversion factors (𝑪𝑫𝑨𝑷
𝑬 ) for examinations of the mandible, calculated from different sources 
in the literature. Conversion factors followed by * denotes the use of nominal DAP displayed by the device. 
HVL followed by * denotes a value either taken from other sources or estimated from the tube voltage and 
filtration. 
𝑪𝑫𝑨𝑷
𝑬  
[µSv/ 
Gycm2] 
Uncer-
tainty 
[k=2] 
FOV 
[cm] 
HVL 
[mm 
Al] Angle Method 
MC-phantom/ 
Nbr. of points CBCT model Source 
64 ± 28 15.4 × 15.4 2.6* 
 
TLD 22 Alphard VEGA Kim et al.50 
63 ± 28 15.4 × 15.4 2.6* 
 
TLD 22 Alphard VEGA Kim et al. 
96 ± 42 10.2 × 10.2 2.6* 
 
TLD 22 Alphard VEGA Kim et al. 
89 ± 39 10.2 × 10.2 2.6*   TLD 22 Alphard VEGA Kim et al. 
140 ± 34 16 × 6 4.2* 360 MC ICRP i-Cat Next Gen Morant et al.49 
160 ± 38 16 × 6 4.2* 180 MC ICRP i-Cat Next Gen Morant et al. 
120 ± 53 6 × 6 4.4 360 MOSFET 20 Newtom 5G Study III 
170 ± 75 10 × 8 - 180 MC Geometric Veraviewepocs R100 Lindfors et al.51 
140 ± 62 8 × 8 - 360 MC Geometric Accuitomo F80 Lindfors et al. 
While there are insufficient data in the literature to establish any general conversion factors, 
the concept of DAP to E conversion factors seem promising. Future studies should 
investigate the possibility to determine positioning specific conversion factors, and quantify 
the effect of FOV size, energy and rotation angle. Other possible complications that should be 
investigated is whether the use of bowtie filters, only present in some CBCT models, 
significantly affects the DAP to E conversion factors.52 These investigations would preferably 
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be performed through MC simulation, due to the combination of high accuracy with the 
ability to relatively quickly perform a large number of simulations on the effect of adjusting 
different examination parameters. If successful, this could reduce or eliminate the need for 
time consuming, model specific, dose studies in dentomaxillofacial CBCT. 
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7 GENERAL CONCLUSIONS AND FUTURE ASPECTS 
• There is a need for more detailed descriptions of the parameters in dose studies to 
allow for generalization of the results.   
• The uncertainties in the determined effective dose are large, especially for methods 
using few measurement points and small FOV. However, future studies are required 
to accurately estimate these uncertainties. 
• The possibility of determening general DAP to effective dose conversion factors 
through Monte Carlo simulations should be investigated. 
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10 ERRATA 
10.1 STUDY III 
Table 2 contains incorrect organ doses. The correct mean organ doses should be as follows. 
Table 2. Mean absorbed organ doses (µGy) for all panoramic protocols 
Organ PAN 1 PAN 2 PAN 3 PAN 4 PAN 5 PAN 6 PAN 7 PAN 8 PAN 9 PAN 10 
Bone Marrow 18 4.9 9.4 2.9 11 10 19 5.4 5.2 4.7 
Thyroid 43 8.1 17 22 30 38 50 19 14 19 
Esophagus 5.1 0.8 4.0 2.4 2.1 4.1 4.7 1.7 0.8 2.3 
Skin 2.4 0.5 0.9 1.1 1.4 1.4 1.3 1.1 0.9 0.7 
Bone surface 18 4.9 9.4 2.9 11 10 19 5.4 5.2 4.7 
Salivary glands 384 16 274 178 307 325 378 80 65 192 
Brain 96 14 17 8.0 19 72 21 15 67 13 
Lymphatic nodes 23 2.4 7.7 4.7 12 13 22 5.7 5.1 6.2 
Extrathoracic airways 367 42 126 79 200 207 350 95 85 103 
Muscle 10 0.8 6.9 4.3 7.7 8.4 10 2.4 1.9 4.6 
Oral mucosa 518 58 170 103 278 280 499 131 116 142 
 
